Samuels Theodore R. II 4

What Happened
Theodore R. Samuels II, a director of Bristol Myers Squibb Co. (BMY), was credited with 3,996.367 deferred share units on February 1, 2026. The filing reports an acquisition (award) valued at $55.05 per share, for a total reported value of $220,000. This was an award of deferred compensation (derivative securities), not an open-market purchase.

Key Details

• Transaction date: 2026-02-01; filing date (accession): 2026-02-03.
• Transaction type/code: Award/Grant (A) — Deferred Share Units (derivative).
• Quantity and price: 3,996.367 units @ $55.05 each; total reported value $220,000.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1 — Each Deferred Share Unit converts into one share of common stock upon settlement; units become settleable when the director leaves the board or on a future date previously specified by the reporting person.
  • F2 — Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Timeliness: Filing appears timely (transaction 2/1/2026; file 2/3/2026), no late-file note in the record provided.

Context
Deferred share units are a form of deferred compensation for non-employee directors and convert into actual shares only upon settlement (often when the director leaves the board or at a specified future date). Such awards reflect compensation arrangements rather than an open-market endorsement of the company; they do not necessarily indicate the director’s short-term market view.